Celldex Therapeutics, Inc.
CLDX
|
$37.98
-1.43%
-1.45%
590K
|
Health Technology
(0.0% 1d) (-7.4% 1m) (3.7% 1y) (0.0% 2d) (-2.5% 3d) (-2.8% 7d) (Infinity% volume)
Earnings Calendar: 2024-02-28
Market Cap: $ 2,123,107,788
http://www.celldex.com
Sec Filling | Patents | 130 employees
(US) Celldex Therapeutics, Inc. engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379. The company was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ.
cancer
add to watch list Paper trade email alert is off
Press-releases
Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria
Published: 2024-04-17 (Crawled : 12:00) - globenewswire.com
CLDX | $37.98 -1.43% -1.45% 590K
|
Health Technology
|
| O: 0.23%
H: 0.0%
C: 0.0%
urticaria study
Celldex Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
Published: 2024-03-08 (Crawled : 12:00) - globenewswire.com
CLDX | $37.98 -1.43% -1.45% 590K
|
Health Technology
|
| O: 1.53%
H: 4.13%
C: 0.48%
conference biopharma global therapeutics
Celldex Therapeutics to Present at TD Cowen’s 44th Annual Health Care Conference
Published: 2024-03-05 (Crawled : 15:30) - globenewswire.com
CLDX | $37.98 -1.43% -1.45% 590K
|
Health Technology
|
| O: -0.95%
H: 1.06%
C: -0.44%
conference health care therapeutics
Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Published: 2024-03-05 (Crawled : 15:00) - globenewswire.com
CLDX | $37.98 -1.43% -1.45% 590K
|
Health Technology
|
| O: -0.95%
H: 1.06%
C: -0.44%
offering therapeutics
Celldex Therapeutics Announces Pricing of Upsized $400 Million Public Offering of Common Stock
Published: 2024-03-01 (Crawled : 03:00) - globenewswire.com
CLDX | $37.98 -1.43% -1.45% 590K
|
Health Technology
|
| O: -0.31%
H: 10.6%
C: 8.29%
million offering therapeutics
Celldex Therapeutics Announces Proposed Public Offering of Common Stock
Published: 2024-02-28 (Crawled : 21:00) - globenewswire.com
CLDX | $37.98 -1.43% -1.45% 590K
|
Health Technology
|
| O: 0.25%
H: 0.41%
C: -6.68%
offering therapeutics
Celldex Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update
Published: 2024-02-26 (Crawled : 12:00) - globenewswire.com
CLDX | $37.98 -1.43% -1.45% 590K
|
Health Technology
|
| O: 3.89%
H: 24.83%
C: 22.97%
year update financial results
Celldex Therapeutics Presents Positive 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria
Published: 2024-02-24 (Crawled : 20:20) - globenewswire.com
CLDX | $37.98 -1.43% -1.45% 590K
|
Health Technology
| Email alert
Add to watchlist
urticaria positive week therapeutics results study
Celldex to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
Published: 2024-02-06 (Crawled : 21:00) - globenewswire.com
CLDX | $37.98 -1.43% -1.45% 590K
|
Health Technology
|
| O: 0.27%
H: 2.52%
C: 1.37%
conference
Celldex Announces Upcoming Presentation of Barzolvolimab Phase 2 Results in Chronic Spontaneous Urticaria at AAAAI 2024
Published: 2024-02-05 (Crawled : 13:00) - globenewswire.com
CLDX | $37.98 -1.43% -1.45% 590K
|
Health Technology
|
| O: -1.1%
H: 5.97%
C: 5.43%
urticaria presentation results
Last 15 days Sec forms
| File Id | Form | Published Date | Transaction Date | Direction | Code | Amount Transacted | Owned Amount |
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 67% | 33% |
Top 10 Gainers
Last 48 Hours Insiders Buying
RXO P 200000 | $19.37 2.32% 0.0% 1M
|
n/a
|
23:00
RKT P 380 | $11.68 1.3% 0.17% 1.9M
|
Finance
|
22:30
HROW P 29400 | $10.43 -3.87% -4.03% 680K
|
Health Technology
|
22:30
BCDA P 2750 | $0.377 -1.4% 97K
|
Health Technology
|
22:00
RMCF | $3.67 3.38% 3.27% 11K
|
Consumer Non-Durables
|
20:10